Cactus Life Sciences
16.4.2024 18:22:07 CEST | ACCESS Newswire | Press release
Fishawack Health Founder's Deep History in Healthcare Communications Blends Nicely with Global Scientific Communications Agency's Upcoming Buy-and-Build Strategy
PRINCETON, NJ / ACCESSWIRE / April 16, 2024 / Cactus Life Sciences, a leading global scientific communications agency that works with blue chip pharma and biotechnology companies, announced today that Oliver Dennis has joined them as Chairman, to work alongside Co-founder, Anurag Goel.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Cactus Life Sciences, headquartered in Princeton, New Jersey was formed in 2010 and is best known for its transformational global operating models that provide best in class science, innovation, and efficiency. "We're delighted to have someone with Oliver's experience of growing businesses join the team," said Anurag. "Cactus Life Sciences is about to undertake an exciting buy and build strategy. And Oliver is the perfect addition with his deep history in healthcare communications having founded Fishawack Health® (now Avalere®)."
During Oliver's tenure at Fishawack, he acquired 17 businesses over 13 years including medical communications and branding agencies, as well as strategic healthcare consultancies and market access and HEOR advisory firms. He led 4 management buy outs to take the business from a start-up to over 1400 people across 22 offices, spanning San Diego to Singapore. Oliver will specifically help shape the future vision for Cactus Life Sciences as the healthcare communications agency partner of the future (strategic, agile, tech-enabled, and outcomes focused) to take on traditional agencies which have lost agility and identity in the pursuit of maximizing profit. He will play an active role in driving the inorganic growth strategy for the business, while pursuing his passion for bringing people together from different businesses and disciplines to collaborate on better outcomes for clients, patients, and our people.
"I've been following Cactus over the last 10 years and they're a great organization. I'm excited to be joining them. They've grown consistently and they have the ambition to become the next generation challenger brand to the traditional players in the market," said Oliver. "This is an opportunity to do something with a greater focus on solving client challenges, improving health outcomes, and nurturing our people."
"Too many companies get to a size where they lose their sense of purpose, values, and forget about individuality. As we work toward transforming Cactus Life Sciences into an agency of the future, we want to ensure that we do so while ensuring that patients and our people are at the core of everything we do," said Elvira D'souza, President of Cactus Life Sciences.
About Cactus Life Sciences (cactuslifesciences.com) Cactus Life Sciences is a medical communication company that provides scientific strategy and content across the healthcare continuum, anywhere in the world─with a focus on science, innovation, and efficiency. We work alongside leading healthcare companies to establish the optimal role of medicines and encourage positive behaviors (physician and patient) that improve patient outcomes. CACTUS has offices in Princeton, London, Aarhus, Singapore, Beijing, Shanghai, Seoul, Tokyo, and Mumbai.
Contact Information:
Laura Perry
Vice President of Strategy & Marketing
laura.perry@cactusglobal.com
7327121005
SOURCE: Cactus Life Sciences
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Announces First Siemens Turbines Arrive at Port of Houston21.7.2026 22:30:00 CEST | Press release
Arrival marks an important milestone in the development of Fermi's Project Matador SGT6-5000F natural gas turbines will anchor what is expected to be the nation's largest combined-cycle natural gas project DALLAS, TX / ACCESS Newswire / July 21, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced the arrival of three Siemens Energy SGT6-5000F natural gas turbines at the Port of Houston. Together, the three turbines are rated at up to 780 megawatts in simple-cycle mode. They are bound for Fermi's Project Matador, an advanced energy and AI campus near Amarillo, Texas. This marks one of the project's largest single power-equipment moves, and it keeps Fermi well ahead of competitors in bringing gigawatt-scale power online. The delivery is the latest in a fast run of milestones. Over the past couple of weeks, Fermi selected TSK, Spain's largest power-focused EPC firm, for early works on its phase-two turbines and brought in Prim
GA-ASI and MBDA Commit to Weapons Collaboration21.7.2026 16:00:00 CEST | Press release
Companies Will Integrate SPEAR Onto MQ-9B and Gambit 6 SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and MBDA have announced a commitment to integrate the European missile-maker's SPEAR precision strike weapons onto new aircraft built by the American uncrewed aircraft manufacturer. GA-ASI President David R. Alexander and MBDA UK Managing Director Chris Allam signed a memorandum of understanding that outlined the agreement at the Farnborough International Airshow 2026. The companies will work together to ensure the MQ-9B remotely piloted aircraft and Gambit 6 collaborative combat aircraft (CCA) can carry and use the SPEAR weapons. "We've built an excellent business relationship with MBDA as part of the integration of the Brimstone missile onto the UK's Protector," said Mr. Alexander. "So, working with MBDA to enable SPEAR on our broader MQ-9B line, and our Gambit CCA, feels like a very natural extension of our partnership." Protect
CHAR Tech Welcomes France's Regulatory Advance Opening Biogas Certificate Support to Pyrolysis21.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 21, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) France proposes opening its flagship renewable gas support scheme (the CPB) to pyrolysis, putting CHAR Tech's HTP technology on the same footing as established production routes in one of Europe's largest gas markets Directly strengthens the HTP project pipeline being developed in France by CHAR Tech's partner GazoTech GazoTech's lead project, Bio-Méthane Provence, is being developed to deploy CHAR Tech's HTP platform to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today welcomed a significant regulatory development in France that, if adopted, would open the country's flagship long-term support mechanism for renewable gas to pyrolysis-based production. The development materially str
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom